GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avrobio Inc (NAS:AVRO) » Definitions » Sloan Ratio %

Avrobio (Avrobio) Sloan Ratio % : -9.62% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Avrobio Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Avrobio's Sloan Ratio for the quarter that ended in Dec. 2023 was -9.62%.

As of Dec. 2023, Avrobio has a Sloan Ratio of -9.62%, indicating the company is in the safe zone and there is no funny business with accruals.


Avrobio Sloan Ratio % Historical Data

The historical data trend for Avrobio's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avrobio Sloan Ratio % Chart

Avrobio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial -1.85 -7.27 -9.14 -8.10 -9.62

Avrobio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -9.62

Competitive Comparison of Avrobio's Sloan Ratio %

For the Biotechnology subindustry, Avrobio's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avrobio's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avrobio's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Avrobio's Sloan Ratio % falls into.



Avrobio Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Avrobio's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(12.157--63.19
-85.076)/101.093
=-9.62%

Avrobio's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(12.157--63.19
-85.076)/101.093
=-9.62%

Avrobio's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -24.957 (Mar. 2023 ) + 67.476 (Jun. 2023 ) + -21.577 (Sep. 2023 ) + -8.785 (Dec. 2023 ) = $12.16 Mil.
Avrobio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -20.284 (Mar. 2023 ) + -14.652 (Jun. 2023 ) + -20.223 (Sep. 2023 ) + -8.031 (Dec. 2023 ) = $-63.19 Mil.
Avrobio's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -0.008 (Mar. 2023 ) + 83.736 (Jun. 2023 ) + 1.198 (Sep. 2023 ) + 0.15 (Dec. 2023 ) = $85.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avrobio  (NAS:AVRO) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Avrobio has a Sloan Ratio of -9.62%, indicating the company is in the safe zone and there is no funny business with accruals.


Avrobio Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Avrobio's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Avrobio (Avrobio) Business Description

Traded in Other Exchanges
N/A
Address
100 Technology Square, Sixth Floor, Cambridge, MA, USA, 02139
Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.
Executives
Azadeh Golipour officer: Chief Technology Officer ONE KENDALL SQUARE, BLD. 300 - SUITE 201, CAMBRIDGE MA 02139
Essra Ridha officer: Chief Medical Officer C/O AVROBIO, INC., ONE KENDALL SQUARE, BLDG 300 - SUITE 201, CAMBRIDGE MA 02139
Philip J. Vickers director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Christopher Mason officer: Chief Scientific Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Phillip B. Donenberg director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Diana Escolar officer: Chief Medical Officer C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Gail M Farfel director 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Deanna M Petersen officer: Chief Business Officer 45 FIRST AVENUE, WALTHAM MA 02451
Geoffrey Mackay director, officer: See Remarks C/O AVROBIO, INC., ONE KENDALL SQ, BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Christopher Paige director C/O AVROBIO INC, ONE KENDALL SQ, BLDG 300, STE 201, CAMBRIDGE MA 02139
Atlas Venture Fund X, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, Llc other: See Remarks 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, L.p. other: See Remarks 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund I, L.p. other: See Remarks 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Bruce Booth director 890 WINTER STREET, SUITE 320, WALTHAM MA 02451